BGNE BeiGene, Ltd.

37.46
-0.94  -2%
Previous Close 38.40
Open 38.31
Price To book 4.95
Market Cap 1.49B
Shares 39,725,000
Volume 39,048
Short Ratio 11.85
Av. Daily Volume 101,335

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 preliminary data to be presented at ASCO June 5, 2017. Abstract 3013.
BGB-A317 and BGB-290
Solid tumors
Phase 3 dosing of China based trial announced March 2, 2017.
BGB-3111
Relapsed or refractory mantle cell lymphoma (MCL)
Phase 3 trial initiation announced January 25, 2017.
BGB-3111
Waldenström’s macroglobulinemia

Latest News

  1. BeiGene to Present at the 2017 UBS Global Healthcare Conference
  2. BeiGene Reports First Quarter 2017 Financial Results
  3. ETFs with exposure to BeiGene Ltd. : April 26, 2017
  4. BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting
  5. BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317
  6. BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
  7. Blog Coverage Agenus Announced Restructuring of Business
  8. BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017
  9. BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results
  10. BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL
  11. BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility
  12. BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting
  13. BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111
  14. BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference
  15. Beigene Ltd (ADR) (BGNE): Here’s Our Take
  16. Do Hedge Funds Love Nobilis Health Corp (USA) (HLTH)?